Can I Take Vitamin B6 with GHK-Cu?

What GHK-Cu Is and How It Works

GHK-Cu is a naturally occurring copper-binding tripeptide composed of glycine, histidine, and lysine, first isolated from human plasma by Loren Pickart in 1973 [1]. It binds Cu²⁺ with high affinity (dissociation constant approximately 10⁻¹⁴ M), which is central to its proposed biological activity [2].

Tissue-Repair and Signaling Roles

Research in cell and animal models shows GHK-Cu stimulates collagen synthesis, activates superoxide dismutase, and up-regulates a range of wound-healing genes [3]. A 2012 analysis of gene-expression data by Pickart and Margolina identified more than 4,000 human genes modulated by GHK, with enrichment in pathways governing DNA repair and anti-inflammatory signaling [4].

Regulatory and Compounding Status

GHK-Cu is not FDA-approved as a finished drug product. Compounding pharmacies operating under 503A of the Federal Food, Drug, and Cosmetic Act may prepare it for individual patients under a valid prescription [5]. The FDA's position on compounded peptides has shifted in recent years; practitioners should verify current compounding-eligible-ingredient status directly with their compounding pharmacy before prescribing.

Topical Versus Injectable Routes

Most commercially available GHK-Cu products are topical serums. Systemic copper absorption from intact skin is low. The interaction considerations in this article apply primarily to subcutaneous or intramuscular GHK-Cu injections compounded for clinical use, where measurable copper delivery to circulation is more plausible.

What Vitamin B6 Does at Different Doses

Vitamin B6 (pyridoxine, pyridoxal, pyridoxamine) is a water-soluble cofactor in over 100 enzymatic reactions, including amino acid transamination, neurotransmitter synthesis, and heme production [6]. The distinction between nutritional and pharmacological dosing drives nearly every safety conversation about B6.

Nutritional Range (Under 50 mg/Day)

The Recommended Dietary Allowance for B6 in adults is 1.3 to 1.7 mg/day [6]. Doses up to 10 mg are common in standard multivitamins. At these levels, B6 is considered safe and well tolerated. No interaction with copper-binding peptides has been documented at nutritional intakes.

Therapeutic Range (50 to 200 mg/Day)

Clinicians sometimes prescribe B6 in this range for premenstrual syndrome, nausea of pregnancy (as part of doxylamine/pyridoxine formulations), and homocysteine lowering. A 2019 Cochrane review found pyridoxine at 30 to 75 mg/day reduced nausea scores in pregnancy [7]. At the lower end of this band, neuropathy risk is low but not zero; the NIH Office of Dietary Supplements notes the Tolerable Upper Intake Level (UL) for adults is 100 mg/day [6].

Pharmacological Range (Above 200 mg/Day)

Sustained B6 above 200 mg/day produces sensory peripheral neuropathy in a dose- and duration-dependent pattern [8]. A case series published in the New England Journal of Medicine documented severe ataxia and sensory loss in patients consuming 2,000 to 6,000 mg/day, with partial recovery after discontinuation [8]. More recent reports in JAMA described neuropathy at doses as low as 200 mg/day taken for several years [9].

The Theoretical Interaction Between GHK-Cu and Vitamin B6

No randomized controlled trial, pharmacokinetic study, or case report in PubMed directly examines a GHK-Cu and vitamin B6 drug-drug interaction. The concern is theoretical but biochemically grounded.

Copper as a Shared Variable

Pyridoxal-5-phosphate (PLP), the active form of B6, is synthesized by pyridox(am)ine-5-phosphate oxidase (PNPO), an enzyme that requires flavin mononucleotide and is modestly sensitive to metal ion availability [10]. Copper excess or deficiency can alter enzyme kinetics in cell models, though human clinical significance at typical GHK-Cu doses has not been established [10].

GHK-Cu delivers Cu²⁺ in a chelated, bioavailable form. Injected preparations raise the question of whether systemic copper loading could indirectly influence B6 metabolism. The effect, if real, is expected to be small given that normal plasma copper is approximately 70 to 140 mcg/dL and typical GHK-Cu dosing adds only micrograms of copper per injection [2].

Pharmacodynamic Neuropathy Concern

Both high-dose B6 and copper toxicity independently cause peripheral neuropathy [8] [11]. Whether the two interact additively or synergistically to lower the neuropathy threshold is unknown. Prudence suggests treating them as potentially additive until evidence clarifies the relationship. No pharmacokinetic interaction (altered absorption, metabolism, or clearance of either compound) has been identified in published literature.

A Practical Risk-Stratification Framework

HealthRX clinicians use a three-tier approach when evaluating this combination in patient stacks:

Tier 1 (Low concern): Topical GHK-Cu plus dietary or low-dose supplemental B6 <50 mg/day. No specific monitoring beyond routine history.

Tier 2 (Moderate concern): Injectable GHK-Cu plus B6 in the 50 to 100 mg/day range. Baseline neurological symptom screen; serum copper at 12 weeks if injections continue.

Tier 3 (High concern): Injectable GHK-Cu plus B6 above 100 mg/day for any indication. Requires explicit prescriber review, documented rationale, and periodic nerve-conduction monitoring if continued beyond 8 weeks.

Dose-Separation Windows

A formal dose-separation recommendation backed by clinical trial data does not exist for this combination. The rationale for separation comes from general pharmacokinetic principles. GHK-Cu injections produce a peak in plasma copper roughly 30 to 90 minutes post-injection based on copper-peptide pharmacokinetic modeling [2]. Taking high-dose oral B6 at least 2 hours before or after an injection minimizes theoretical overlap at the time of peak copper availability. This 2-hour window is a conservative clinical estimate, not a proven interval.

For topical GHK-Cu, dose separation is not considered necessary because transdermal copper bioavailability is too low to produce meaningful systemic copper fluctuations.

What the Guidelines Say About Copper and B6 Safety

NIH Dietary Supplement Office: B6 Upper Limit

The NIH Office of Dietary Supplements states: "The UL for vitamin B6 for adults is 100 mg/day from all sources. Intakes above this level can cause peripheral neuropathy" [6]. This guidance predates any consideration of concurrent copper-binding peptide use, so it does not address the combination directly.

FDA on Compounded Peptides

The FDA has published guidance indicating that compounded drug products must be prepared only from bulk substances that appear on specific approved lists or meet criteria under 503A [5]. Prescribers ordering GHK-Cu from a compounding pharmacy should confirm that the pharmacy is operating in compliance with current FDA guidance and state pharmacy board requirements.

Copper Toxicity: WHO Reference Values

The World Health Organization sets a provisional tolerable daily intake for copper at 0.5 mg/kg body weight per day [12]. For a 70 kg adult, that is 35 mg/day. Compounded GHK-Cu injections typically supply micrograms to low milligrams of copper per dose, well below this threshold [2]. Chronic accumulation over months of daily use has not been studied in humans.

Monitoring Recommendations

Baseline Assessment Before Starting the Combination

Before beginning injectable GHK-Cu in a patient already taking B6 at any dose above 50 mg/day, document:

• Current B6 dose and duration of use
• Any baseline neurological symptoms (paresthesia, balance disturbance, burning feet)
• Serum copper and ceruloplasmin if the patient has a personal or family history of Wilson's disease or copper metabolism disorders [11]

On-Treatment Monitoring

For patients continuing this combination for more than 8 weeks, a neurological symptom review at each visit is reasonable. Routine serum B6 (plasma PLP) measurement can confirm whether B6 levels are in a safe range; plasma PLP above 200 nmol/L is associated with neuropathy risk in some longitudinal data [9].

When to Stop One or Both

Stop high-dose B6 immediately if the patient reports new-onset paresthesia, gait instability, or burning pain in distal extremities. Discontinuing GHK-Cu injections pending evaluation is appropriate if there is any uncertainty about the contribution of copper loading to neurological symptoms.

Special Populations

Patients on Isoniazid or Other B6-Depleting Drugs

Isoniazid, cycloserine, and hydralazine all deplete B6 by forming hydrazones with pyridoxal [13]. These patients often receive supplemental B6 at 25 to 50 mg/day to prevent isoniazid-induced neuropathy, per standard infectious disease guidance [13]. Adding injectable GHK-Cu to this regimen requires careful review, as the prescribing clinician must balance B6 repletion against the copper loading from GHK-Cu. The two goals do not typically conflict at standard doses, but documentation and monitoring matter.

Patients With Wilson's Disease or Copper Overload Conditions

Wilson's disease involves pathological copper accumulation due to ATP7B mutations [11]. GHK-Cu is contraindicated in this population without specialist hepatology or metabolism oversight. B6 status in Wilson's disease is generally not affected by the copper accumulation itself, but the combination of any exogenous copper source plus high-dose B6 adds unacceptable uncertainty in these patients.

Pregnant and Breastfeeding Patients

Doxylamine-pyridoxine (Diclegis/Bonjesta) at doses of 20 to 40 mg pyridoxine per day is FDA-approved for nausea of pregnancy [14]. GHK-Cu has no established safety data in pregnancy. Absent controlled trial data, injectable GHK-Cu should not be used during pregnancy regardless of B6 status.

Practical Stacking Guidance

The majority of people taking topical GHK-Cu serums and a standard B6-containing multivitamin face no meaningful interaction risk. The clinical concern concentrates on three scenarios: injectable GHK-Cu plus high-dose B6, patients with underlying copper metabolism disorders, and patients already taking drugs that alter B6 or copper handling.

For those using injectable GHK-Cu at typical compounded doses (commonly 1 to 2 mg per injection, two to three times per week) alongside B6 at 50 mg/day or less, the risk profile is low based on available pharmacological data. Keeping B6 below the NIH UL of 100 mg/day is the clearest actionable threshold [6].

If you are stacking injectable GHK-Cu with a therapeutic B6 dose above 100 mg/day for a specific medical indication, that combination warrants a documented clinical rationale, a baseline neurological screen, and a monitoring plan. No single data source currently quantifies the precise risk increment from adding GHK-Cu to high-dose B6. Clinicians should apply conservative judgment until that evidence exists.